AstraZeneca
30-Second Executive Brief
Executive Assessment
AstraZeneca functions as an established institution within Healthcare & Life Sciences, backed by 47% sourcing coverage, with accelerating strategic relevance.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- High
- Strategic Momentum
- Accelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 5
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
An Anglo-Swedish pharmaceutical company whose oncology franchise drove H1 2026 oncology revenue up 15% to $14.1 billion, led by Tagrisso, Lynparza, Imfinzi, Calquence, and Enhertu. AstraZeneca secured 30 major market approvals and reported positive results from six Phase III programs in 2026, while licensing Dizal Pharmaceutical's oral EGFR inhibitor Zegfrovy for lung cancer to broaden its pipeline beyond its existing oncology portfolio.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Earnings-call mentions
Mentioned by Ionis Pharmaceuticals
“WAINUA is a registered trademark of the AstraZeneca group of companies”
SEC 8-K exhibit (0001140361-26-029960) · Jul 29, 2026
Mentioned by IonQ
“IonQ's newest generation of quantum computers, the IonQ Tempo, is the latest in a line of cutting-edge systems that have been helping customers and partners including Amazon Web Services and AstraZeneca achieve 20x performance results and accelerate innovation in drug discovery, materials science, financial modeling, logistics, cybersecurity, and defense.”
SEC 8-K exhibit (0001193125-26-335040) · Aug 5, 2026
Mentioned by Tempus AI
“Successfully delivered our first oncology foundation model to AstraZeneca”
SEC 8-K exhibit (0001193125-26-326083) · Jul 30, 2026
Federal contract disclosures
Department of Defense — $500: 8511731821!OTHER MEDICAL
USAspending.gov · Nov 3, 2025
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources
- Bloomberg — AstraZeneca's cancer medicines spur profit growthnews
- AstraZeneca — AstraZeneca licenses novel oral EGFR inhibitor Zegfrovycompany
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding AstraZeneca — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
AstraZeneca's five-drug oncology spread is a structurally different risk profile than Merck's Keytruda-dependent model
33% confidenceAstraZeneca's H1 2026 oncology revenue grew 15% to $14.1 billion across five separate drugs (Tagrisso, Lynparza, Imfinzi, Calquence, Enhertu), and it continues licensing in new assets like Zegfrovy, rather than depending on one dominant franchise.
This is InsightNodes' own interpretive read: compared with Merck, whose oncology revenue is overwhelmingly concentrated in Keytruda, AstraZeneca's oncology growth is spread across five drugs with staggered patent expiries, meaning no single loss-of-exclusivity event can produce a cliff of Keytruda's scale -- this diversified-portfolio approach trades slower single-drug blockbuster upside for materially lower concentration risk, a distinction worth weighing when comparing oncology-focused pharma peers.
InsightNodes analysis of AstraZeneca H1 2026 results · Aug 14, 2026
AstraZeneca's Timeline
A sourced, dated history of AstraZeneca's key moments — founding to present.
Jun 2026 · Licenses Zegfrovy from Dizal Pharmaceutical
AstraZeneca entered an exclusive global license agreement with Dizal Pharmaceutical for the novel oral EGFR inhibitor Zegfrovy for lung cancer.
Jul 2026 · H1 2026 oncology revenue up 15% to $14.1B
AstraZeneca reported H1 2026 oncology revenue growth of 15% to $14.1 billion, driven by Tagrisso, Lynparza, Imfinzi, Calquence, and Enhertu.